Preferred Label : HIV-1 Protease Inhibitor ASC09/Ritonavir;
NCIt synonyms : HIV-1 Protease Inhibitor ASC09/Ritonavir ASC09F; Protease Inhibitor ASC09/Ritonavir;
NCIt definition : A fixed combination agent containing ASC09, an orally bioavailable human immunodeficiency
virus type 1 (HIV-1) protease inhibitor, and ritonavir, a potent CYP3A4 inhibitor,
with potential activity against HIV and certain other RNA viruses. Upon oral administration
of ASC09F, the HIV-1 protease inhibitor ASC09 selectively targets and binds to the
active site of HIV-1 protease, and inhibits the dimerization and catalytic activity
of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol
polyproteins in HIV-infected cells. This inhibition leads to the production of immature,
non-infectious viral proteins that are unable to form mature virions, and prevents
HIV replication. In addition, ASC09 may also inhibit viral proteases from other RNA
viruses, thereby preventing their replication. Ritonavir inhibits cytochrome P450
(CYP) 3A4 (CYP3A4)-mediated metabolism of ASC09, which is a CYP3A4 substrate. This
leads to an increased concentration and half-life of ASC09 as compared to the administration
of ASC09 without ritonavir.;
Molecule name : AS C09F; AS-C09F;
NCI Metathesaurus CUI : CL1406848;
Origin ID : C172816;
UMLS CUI : C5419876;
Semantic type(s)
- concept_is_in_subset
